Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.
This phase I/II trial is evaluating how safe and tolerable a new targeted therapy (LM-302) is when combined with immunotherapy (toripalimab) in people with advanced solid cancers
Status : Recruiting
This phase I/II dose escalation and expansion study is trying to understand how safe and effective a new drug (TAK-280) is in people with locally advanced or metastatic cancer that is unable to be removed with surgery
This phase I trial is evaluating how safe and effective targeted therapy (MK-1084) is alone in people with advanced solid cancers with KRASG12C mutation, and when it is combined with immunotherapy (pembrolizumab) in people with non-small cell cancer with KRASG12C mutation
This phase II study is trying to understand the effectiveness of combining a new drug (CEND-1), compared to a placebo, with chemotherapy (gemcitabine and nab-paclitaxel) in people with untreated metastatic pancreatic cancer
This phase I/II trial is exploring increasing doses of a new cancer drug (YH003) in combination with a targeted therapy with the aim of identifying and evaluating maximum tolerated/recommended dose
This phase II study is evaluating how safe and effective a targeted therapy (olinvacimab) in combination with immunotherapy (pembrolizumab) is in people with metastatic triple-negative breast cancer
This phase III trial is trying to determine whether targeted therapy (Sacituzumab Govitecan-hziy) is more effective than chemotherapy (Docetaxel) in people with advanced or metastatic non-small cell lung cancer who have had previous treatment
This Phase III trial is evaluating the effectiveness of a targeted therapy (Sacituzumab Govitecan-hziy) compared to chemotherapy (paclitaxel, docetaxel or vinflunine) in people with bladder cancer that is unable to be treated with surgery
This phase I/II trial is trying to understand how safe, tolerable and effective a targeted therapy (AU-007), with or without immunotherapy (aldesleukin), is in people with advanced or metastatic solid cancer
This phase II trial is evaluating how safe and effective a targeted therapy (Mirvetuximab Soravtansine) in people with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression
Looking for a trial? Use the search functionality to find the trial you are finding.